Kurse werden geladen...
Prognose
Kaufen | 1 |
Halten | 1 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site
USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologies CLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 20, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of Keck Medical Center of USC as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial site.» Mehr auf globenewswire.com
Aclarion Announces Texas Back Institute as New CLARITY Trial Site
Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of the Texas Back Institute (TBI) as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial site.» Mehr auf globenewswire.com
Aclarion Welcomes Advocate Health as CLARITY Trial Site
Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of Advocate Aurora Research Institute, part of Advocate Health, as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) site.» Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 17,55k | 87,32% |
Bruttoeinkommen | −4,15k | 91,78% |
Nettoeinkommen | −1,88 Mio | 15,28% |
EBITDA | −1,38 Mio | 26,25% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 3,75 Mio€ |
Anzahl Aktien | 582,37k |
52 Wochen-Hoch/Tief | 3.023,94€ - 5,36€ |
Dividenden | Nein |
Beta | 1,21 |
KGV (PE Ratio) | −2,47 |
KGWV (PEG Ratio) | 0,05 |
KBV (PB Ratio) | 1,04 |
KUV (PS Ratio) | 79,51 |
Unternehmensprofil
Aclarion, Inc. ist ein Technologieunternehmen im Gesundheitswesen, das in den Vereinigten Staaten Softwareanwendungen für die Magnetresonanzspektroskopie (MRS) entwickelt. Es bietet die NOCISCAN-LS Post-Processor-Suite an, die NOCICALC-LS umfasst, das die erfassten Bandscheiben-MRS-Daten empfängt und verarbeitet, um die Werte degenerativer Schmerz-Biomarker zu berechnen, sowie NOCIGRAM-LS, eine Software zur Unterstützung klinischer Entscheidungen. Das Unternehmen war früher als Nocimed, Inc. bekannt und änderte im Dezember 2021 seinen Namen in Aclarion, Inc. Aclarion, Inc. wurde im Jahr 2008 gegründet und hat seinen Sitz in San Mateo, Kalifornien.
Name | ACLARION NEW DL-,00001 Aktie |
CEO | Brent Ness |
Sitz | Broomfield, ca USA |
Website | |
Industrie | Gesundheitswesen: Ausstattung und Produkte |
Börsengang | |
Mitarbeiter | 5 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | ACON |
Assets entdecken
Shareholder von ACLARION NEW DL-,00001 Aktie investieren auch in folgende Assets